A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
NCT ID: NCT06817382
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
12 participants
INTERVENTIONAL
2025-07-22
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1: Cohort 1
Participants aged 3 to \<5 years will receive a single dose level 1 of INS1201 by IT injection on Day 1.
INS1201
Suspension for IT injection.
Part 1: Cohort 2
Participants aged 3 to \<5 years will receive a single dose level 2 of INS1201 by IT injection on Day 1.
INS1201
Suspension for IT injection.
Part 2: Cohort 3
Participants aged 2 to \<3 years will receive a single dose level 1 of INS1201 by IT injection on Day 1.
INS1201
Suspension for IT injection.
Part 2: Cohort 4
Participants aged 2 to \<3 years will receive a single dose level 2 of INS1201 by IT injection on Day 1.
INS1201
Suspension for IT injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INS1201
Suspension for IT injection.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ambulatory -as defined as the ability to walk at least 10 meters unassisted (ie, without personal assistance or use of any assistive devices) Note: children who have not yet developed the ability to walk by the time of screening (for whatever reason) will not be eligible for the study.
* Has a definitive diagnosis of DMD prior to Screening or as part of Screening based on genetic testing. Note that participants who rescreen do not have to repeat genetic testing for the diagnosis of DMD if one is already on file. Genetic reports must describe a frameshift deletion, frameshift duplication, premature stop ("nonsense"), canonical splice site mutation, or other pathogenic variant in the DMD gene fully contained between exons 18 to 58 (inclusive) that is expected to lead to absence of a functional dystrophin protein (mutations in exons 1-17 or 59-71 are therefore not permitted).
* Able to cooperate with motor assessment testing.
* Has received vaccinations recommended for the participant's age and DMD disease according to Centers for Disease Control and Prevention (CDC) Child and Adolescent Immunization Schedule by Age, World Health Organization, or local recommendation incorporating the Advisory Committee on Immunization Practices (ACIP) Vaccine Recommendations and Guidelines for Patients with Altered Immunocompetence.
Exception is made for seasonal influenza and coronavirus disease 2019 (COVID-19) vaccines, for which shared decision-making with the participant's physician is encouraged.
Exclusion Criteria
* Oligonucleotide-based exon skipping or small molecule stop codon readthrough-promoting therapies for at least 6 months prior to enrolment.
* Has left ventricular ejection fraction \< 50% on the screening echocardiogram (ECHO) or clinical signs and/or symptoms of cardiomyopathy.
* Has cardiac arrhythmia or significant electrocardiogram (ECG) interval abnormalities.
* Major surgery within 3 months prior to Day 1 or planned surgery or procedures that would interfere with the conduct of the study at any time during this study.
* The presence of any other clinically significant illness, including cardiac, pulmonary, hepatic, renal, hematologic, immunologic/allergic, behavioural disease, infection, unhealed injury, malignancy, concomitant illness, extenuating circumstance, or requirement for chronic drug treatment that, in the opinion of the Investigator:
1. Creates unnecessary risks for undergoing gene transfer;
2. Might compromise the participant's ability to comply with the protocol-required testing or procedures; or
3. Might compromise the participant's well-being, safety, or clinical interpretability.
* Has serological evidence of current, chronic, or active human immunodeficiency virus, hepatitis C, or hepatitis B infection.
* Has signs of clinically significant symptomatic infection (eg, upper respiratory tract infection, pneumonia, pyelonephritis, meningitis) within 4 weeks prior to Day 1.
* Has contraindications for IT administration of the product or for lumbar puncture, such as anatomical abnormalities, bleeding disorders or other medical conditions (eg, spina bifida, meningitis, or significant clotting abnormalities).
* Demonstrates cognitive or developmental delay or impairment that could confound assessment of motor development in the opinion of the Investigator.
* Total serum anti-AAV9 antibody titers of \> 1:50 as determined by ELISA within 14 days of Day 1.
2 Years
4 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insmed Gene Therapy LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USA012
Little Rock, Arkansas, United States
USA010
Davis, California, United States
USA002
Palo Alto, California, United States
Rare Disease Research (USA004)
Atlanta, Georgia, United States
USA008
Rochester, New York, United States
USA006
Columbus, Ohio, United States
USA001
Memphis, Tennessee, United States
USA015
Norfolk, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kendra Stroud
Role: primary
Amanda Marie Figueroa Lopez
Role: primary
Rabia Farooquee
Role: primary
Laura Sutton
Role: primary
Role: primary
Abigail Hanson
Role: primary
Colin Quillivan
Role: primary
Patty Smith
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INS1201-101
Identifier Type: -
Identifier Source: org_study_id